Data at ASCO 2022 Examine Oral Oncolytic Adherence During the COVID-19 Pandemic
We spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the ASCO 2022 Annual Meeting.
Pharmacy Times spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. McAuliff has worked on a study examining the impact of the COVID-19 pandemic on oral oncolytic adherence, and how digital tools could help improve adherence.
Stay tuned on our website and follow us on social media for live coverage of the ASCO 2022 Annual Meeting.
Q: What will you be presenting at the ASCO 2022 Annual Meeting?
Kelly McAuliff, PharmD, BCOP, CSP: Yeah, so the purpose of our study was to evaluate the impact that COVID-19 had on adherence to oral oncolytics amongst members of a large health plan with a diagnosis of ovarian, prostate, or chronic myelogenous leukemia. We additionally studied how digital engagement can limit the impact of COVID-19 on adherence.
Q: What are you most excited for at ASCO this year?
A: I am very excited to see folks visit the exhibitor booths and network with colleagues that I have not had a chance to see in many, many, many months. So, it will be nice to give some hugs, handshakes, and, you know, socialize in person.
